Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.59 --0%
Financial Fact:
Weighted-average number of shares - basic: 40.47M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Weighted-average number of shares - basic: 40.47M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.
The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
